117 related articles for article (PubMed ID: 37676119)
1. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).
Hehir MK; Conaway M; St Sauveur AB; Feb K; Kolb NA; Waheed W; McNeish BL; Tweedy N; Burns TM
Muscle Nerve; 2024 Jan; 69(1):32-39. PubMed ID: 37676119
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
3. The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events.
Hehir MK; Conaway M; Clark EM; Aronzon DB; Kolb N; Kolb A; Ruzhansky K; Sadjadi R; De Sousa EA; Burns TM
PLoS One; 2022; 17(2):e0262109. PubMed ID: 35176061
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of outcome measures for myasthenia gravis subgroups.
Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
[TBL] [Abstract][Full Text] [Related]
5. Validation of Spanish version of 15-item myasthenia gravis quality-of-life questionnaire.
Contreras JP; Salinas R; Vidal C; Hoffmeister L; Wolfe GI; Cea G
Acta Neurol Scand; 2021 Nov; 144(5):546-552. PubMed ID: 34131909
[TBL] [Abstract][Full Text] [Related]
6. Physician- and self-assessed myasthenia gravis activities of daily living score.
Lee HL; Min JH; Seok JM; Cho EB; Cho HJ; Kim YD; Kim BJ
Muscle Nerve; 2018 Mar; 57(3):419-422. PubMed ID: 28796382
[TBL] [Abstract][Full Text] [Related]
7. Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores.
Dewilde S; Janssen MF; Tollenaar NH; Vanoli F; Frangiamore R; Phillips G; Paci S; Mantegazza R; Meisel A; Stascheit F
Muscle Nerve; 2023 Jul; 68(1):65-72. PubMed ID: 37144893
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
9. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
10. The Myasthenia Gravis-specific Activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients.
Rozmilowska IM; Adamczyk-Sowa MH; Czyzewski D
Neurol Neurochir Pol; 2018; 52(3):368-373. PubMed ID: 29370887
[TBL] [Abstract][Full Text] [Related]
11. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
13. Efgartigimod in refractory autoimmune myasthenia gravis.
Remijn-Nelissen L; Tannemaat MR; Ruiter AM; Campman YJM; Verschuuren JJGM
Muscle Nerve; 2024 Jun; ():. PubMed ID: 38899431
[TBL] [Abstract][Full Text] [Related]
14. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.
Burns TM; Sadjadi R; Utsugisawa K; Gwathmey KG; Joshi A; Jones S; Bril V; Barnett C; Guptill JT; Sanders DB; Hobson-Webb L; Juel VC; Massey J; Gable KL; Silvestri NJ; Wolfe G; Cutter G; Nagane Y; Murai H; Masuda M; Farrugia ME; Carmichael C; Birnbaum S; Hogrel JY; Nafissi S; Fatehi F; Ou C; Liu W; Conaway M
Muscle Nerve; 2016 Dec; 54(6):1015-1022. PubMed ID: 27220659
[TBL] [Abstract][Full Text] [Related]
15. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
Gratton SM; Herro AM; Feuer WJ; Lam BL
J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
[TBL] [Abstract][Full Text] [Related]
17. Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.
Dewilde S; Qi CZ; Phillips G; Iannazzo S; Janssen MF
Adv Ther; 2023 Apr; 40(4):1818-1829. PubMed ID: 36867327
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in quality of life among patients with myasthenia gravis in China.
Dong D; Chong MK; Wu Y; Kaminski H; Cutter G; Xu X; Li H; Zhao C; Yin J; Yu S; Zhu J
Health Qual Life Outcomes; 2020 Sep; 18(1):296. PubMed ID: 32883289
[TBL] [Abstract][Full Text] [Related]
19. Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale.
Alanazy MH; Abuzinadah AR; Muayqil T
Muscle Nerve; 2019 May; 59(5):583-586. PubMed ID: 30697753
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
